PCSK9 and atherosclerosis: Cardiovascular outcomes trials in patients with established ASCVD have reported a 15%–20% lower risk of major adverse cardiovascular events (MACE) for anti-PCSK9 monoclonal antibodies (Sabatine, 2019).